AC is better than EDI for LC visibility

Article

If the goal is to improve lamina cribrosa (LC) visibility, adaptive compensation (AC) is better than enhanced depth imaging (EDI), according to new research.

If the goal is to improve lamina cribrosa (LC) visibility, adaptive compensation (AC) is better than enhanced depth imaging (EDI), according to new research published in Investigative Ophthalmology and Visual Science. Visibility of the posterior LC remains poor, so it is probably not realistic to use LC thickness as a glaucoma biomarker.

The researchers, from Singapore, French Polynesia and London, compared LC visibility in optic disc images obtained from 60 patients with glaucoma and 60 patients serving as controls. They used three optical coherence tomography (OCT) devices, with and without EDI and AC: They obtained a horizontal B-scan through the centre of the disc using two spectral-domain OCT devices (Spectralis, Heidelberg Engineering; Cirrus, Carl Zeiss Meditec - both with and without EDI) and a swept-source OCT device (DRI, Topcon). The investigators applied AC after they obtained the scans, to improve image quality.

Four masked observers evaluated LC visibility by grading the 1,200 images in random order. They graded the anterior LC on a 0-to-4 scale, the LC insertions on a scale of 0 to 2, and the posterior LC either as 0 or 1. The observers used generalized estimating equations to evaluate the effect on LC visibility of EDI, AC, glaucoma severity and other clinical and demographic factors.

The observers found that anterior LC was the most detectable feature, then LC insertions. “AC improved anterior LC visibility independent of EDI,” they wrote. “Cirrus+EDI+AC generated the greatest anterior LC visibility grades.”

Regarding LC insertions visibility, they said, “DRI+AC was the best method. Visibility of the posterior LC was consistently poor. Neither glaucoma severity nor clinical/demographic factors consistently affected LC visibility.”

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.